Soligenix (SNGX) Expected to Announce Quarterly Earnings on Tuesday

Soligenix (NASDAQ:SNGX) is expected to issue its Q4 2025 results before the market opens on Tuesday, March 31st. Analysts expect the company to announce earnings of ($0.27) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, April 1, 2026 at 4:00 PM ET.

Soligenix Trading Up 0.8%

Shares of SNGX stock opened at $1.21 on Tuesday. The firm has a fifty day simple moving average of $1.22 and a 200-day simple moving average of $1.49. The company has a market capitalization of $12.21 million, a PE ratio of -0.34 and a beta of 1.99. Soligenix has a twelve month low of $1.02 and a twelve month high of $6.23.

Institutional Investors Weigh In On Soligenix

Institutional investors have recently modified their holdings of the stock. XTX Topco Ltd bought a new position in shares of Soligenix during the fourth quarter worth about $37,000. StoneX Group Inc. acquired a new stake in Soligenix during the fourth quarter valued at approximately $50,000. Geode Capital Management LLC raised its stake in Soligenix by 88.8% during the fourth quarter. Geode Capital Management LLC now owns 80,401 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 37,811 shares in the last quarter. Jane Street Group LLC bought a new position in Soligenix during the 4th quarter worth approximately $51,000. Finally, Banco BTG Pactual S.A. bought a new position in Soligenix during the 3rd quarter worth approximately $54,000. Institutional investors and hedge funds own 3.60% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Soligenix in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $6.00.

About Soligenix

Soligenix, Inc is a clinical‐stage biopharmaceutical company focused on developing vaccines and therapeutics to address unmet medical needs in rare diseases and biodefense. The company leverages proprietary technologies to create novel vaccine adjuvants, small‐molecule innate defense regulators and photodynamic therapies aimed at improving patient outcomes in orphan indications and protecting public health against biological threats.

The company’s pipeline is organized into two core divisions.